Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 12/20 | 0.35 |
| ▸ | MAPT | P10636 | 10/20 | 0.35 |
| ▸ | GSK3B | P49841 | 7/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14891994 | 1.00 | GSK3A (0.35) | GSK3AMAPTGSK3BNPY5RATR | |
| SCHEMBL14891672 | 0.98 | MAPT (0.35) | GSK3AMAPTGSK3BNPY5RATR | |
| SCHEMBL14892173 | 0.98 | MAPT (0.35) | GSK3AMAPTGSK3BNPY5RATR | |
| SCHEMBL14906150 | 0.81 | PIM2 (0.38) | GSK3AMAPTGSK3BPIM1CDK2 | |
| SCHEMBL1911277 | 0.80 | MAPT (0.37) | GSK3AMAPTGSK3BPIM1CDK2 | |
| SCHEMBL1911219 | 0.80 | MAPT (0.37) | GSK3AMAPTGSK3BPIM1 | |
| SCHEMBL14892798 | 0.80 | MET (0.37) | GSK3A | |
| SCHEMBL14892188 | 0.80 | MET (0.37) | GSK3A | |
| SCHEMBL14906097 | 0.78 | GSK3B (0.52) | GSK3BATRPRKCQ | |
| SCHEMBL1910925 | 0.77 | GSK3A (0.39) | GSK3AMAPTGSK3BPIM1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | PIM1, GSK3A, GSK3B | GSK3A 2/4885MAPT 2904/4885GSK3B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.